

# Što možemo naučiti iz obrazaca znanstvenog objavljivanja tijekom pandemije COVID-19

---

Homolak, Jan

Conference presentation / Izlaganje na skupu

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:759976>

Rights / Prava: [In copyright](#) / [Zaštićeno autorskim pravom](#).

Download date / Datum preuzimanja: **2025-03-23**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine  
Digital Repository](#)





Sveučilište u Zagrebu  
Medicinski fakultet  
Središnja medicinska knjižnica

2021 MICC  
Medical Information Conference Croatia





Wolters Kluwer

Ovid

Što možemo naučiti iz obrazaca znanstvenog objavljivanja  
tijekom pandemije COVID-19?

Jan Homolak  
Zavod za Farmakologiju  
Medicinski fakultet Sveučilišta u Zagrebu



Homolak, J. & Kodvanj, I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. *Int. J. Antimicrob. Agents* 56, 106044 (2020) doi:10.1016/j.ijantimicag.2020.106044.



**Our world is a mess.  
A large part of this mess is made of  
COVID-19 information.**



[https://www.slideshare.net/AbbyCovert/how-to-make-sense-of-any-mess/59-20\\_ways\\_to\\_organize\\_a](https://www.slideshare.net/AbbyCovert/how-to-make-sense-of-any-mess/59-20_ways_to_organize_a)



- **Enormno puno istraživanja**
- **Kvantiteta > kvaliteta**
- **Izraziti „obrtaj“**
- **Podaci u pravilu nedostupni – a s obzirom na (ne)kvalitetu istraživanja su ključni !**

# OBRASCI OBJAVLJIVANJA

DOBRI

Dear Dr. Homolak,

Thank you for your submission to the Journal of Medical Virology.

Wiley has signed up to the World Health Organization (WHO) and Wellcome Trust commitment to share research data and findings relevant to the novel coronavirus outbreak. Please find more information here:


<https://wellcome.ac.uk/press-release/sharing-research-data-and-findings-relevant-novel-coronavirus-covid-19-outbreak>

We request your permission to share this relevant submission directly with the WHO. If you approve, we will share this submission directly with the WHO and indicate that this is a preliminary report that has not been peer reviewed. The WHO would only use this submission for research purposes, it will not be put in the public domain and this will not impact the submission or publication process of your article.

We will not share your submission without your approval. Please be in touch with any questions. We look forward to hearing from you.

Kind regards,  
Ms. Aarthi Sharma  
Journal of Medical Virology  
[JMV@wiley.com](mailto:JMV@wiley.com)


Homolak, J., Kodvanj, I. & Virag, D. Preliminary analysis of COVID-19 academic information patterns: a call for open science in the times of closed borders. *Scientometrics* 1–15 (2020) doi:10.1007/s11192-020-03587-2.






# OBRASCI OBJAVLJIVANJA


DOBRI




Homolak, J., Kodvanj, I. & Virag, D. Preliminary analysis of COVID-19 academic information patterns: a call for open science in the times of closed borders. *Scientometrics* 1–15 (2020) doi:10.1007/s11192-020-03587-2.



# OBRASCI OBJAVLJIVANJA




Kodvanj, I., Homolak, J., Virag, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. bioRxiv (2020) doi:10.1101/2020.11.23.394577.






# OBRASCI OBJAVLJIVANJA

## LOŠI I ZLI



Homolak, J., Kodvanj, I. & Virag, D. Preliminary analysis of COVID-19 academic information patterns: a call for open science in the times of closed borders. *Scientometrics* 1–15 (2020) doi:10.1007/s11192-020-03587-2.



# OBRASCI OBJAVLJIVANJA


## LOŠI I ZLI

**Table 1.** Summary of the analysis of the probability of publishing within 120 days since the first preprint version (a subset of preprints deposited till June 29) and time-to-publishing considering the entire observed period (a subset of preprints deposited till 27 September)<sup>1</sup>. Effects are expressed as odds ratios (OR).

<i>Predictors</i>	Published within 120 days		Published before Nov. 01	
	OR (95% CI)	<i>p</i>	OR (95% CI)	<i>p</i>
COVID-19 vs Not COVID-19	2.04 (1.87 to 2.23)	<0.001	1.42 (1.33 to 1.52)	<0.001
bioRxiv vs medRxiv	1.33 (1.21 to 1.45)	<0.001	1.24 (1.17 to 1.32)	<0.001
≥2 vs 1version	0.72 (0.66 to 0.78)	<0.001	0.90 (0.85 to 0.94)	<0.001

<sup>1</sup> Stratified (by preprinting date of the first version) logistic regression was fitted to the probability of being published within 120 days and over the entire observed period.

Kodvanj, I., Homolak, J., Virag, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. bioRxiv (2020) doi:10.1101/2020.11.23.394577.





# OBRASCI OBJAVLJIVANJA


## LOŠI I ZLI

**Table 2.** Analysis of *submission-to-acceptance* time for published preprints (in days)<sup>1</sup>.

Predictors	Estimates (95% CI)	p
COVID-19 vs Not COVID-19	-38.67 (-42.39 to -34.96)	<0.001
bioRxiv vs medRxiv	0.25 (-3.36 to 3.86)	0.891
≥2 vs 1 preprint version	0.96 (-2.00 to 3.91)	0.526

<sup>1</sup> Linear mixed-effects model (submission date specified as a random effect) was fitted to the number of days between the date of receipt by the journal and date of acceptance. Submission to publication time was identified for 421 COVID-19/bioRxiv (median=49 days), 4191 not-COVID-19/bioRxiv (median=95 days), 1032 COVID-19/medRxiv (median=48 days), 423 not-COVID-19/medRxiv preprints (median=97 days).

Kodvanj, I., Homolak, J., Virag, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. bioRxiv (2020) doi:10.1101/2020.11.23.394577.






# OBRASCI OBJAVLJIVANJA

## LOŠI I ZLI

**Table 3.** The number of retractions/expressions of concern/corrections identified at Retraction Watch Database (RWD), the total number of PubMed articles, and retraction rates (notices/total number of articles) for COVID-19-related articles and articles related to four other viruses/associated diseases, two research fields (epidemiology, immunology).









<i>Topic</i>	<i>RWD count<sup>1</sup></i>	<i>Pubmed count<sup>2</sup></i>	<i>Retraction rate</i>
COVID-19	36	64915	0.55‰
Not COVID-19	306	1428252	0.21‰
HIV	1	10453	0.10‰
Herpes virus	3	2663	1.13‰
Influenza	0	3411	-
Hepatitis virus	0	1321	-
Epidemiology	6	40279	0.15‰
Immunology	8	63577	0.13‰

Kodvanj, I., Homolak, J., Virag, D. & Trkulja, V. Publishing of COVID-19 Preprints in Peer-reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. bioRxiv (2020) doi:10.1101/2020.11.23.394577.




# OBRASCI OBJAVLJIVANJA


## LOŠI I ZLI




Kodvanj, I., Homolak, J., Virag, D. & Trkulja, V. Bibliographic database functionality with respect to missingness of article descriptors and database structure: A case study of the WHO COVID-19 database. [Submitted manuscript] (2020).



# RJEŠENJE?



data-against-covid.org



Sign Up

Log In




You – clinicians, virologists, immunologists – are working around the clock to combat the epidemic. We – machine learners, bioinformaticians, epidemiologists, statisticians – are eager to help. This is the place to post your data and give us tasks: answer your questions, analyze your data, make predictions. Just remember that to help you, we need data. If you're unsure where to begin, take a look at our [FAQ + Guidelines](#).

## 🚩 List of PIs Supporting this Endeavour

■ I have data science skills...



# RJEŠENJE?



## Rescale, Google Cloud, and Microsoft Azure to Accelerate COVID-19 Vaccine with Cloud Supercomputing


High performance computing resources immediately available at no cost to engineers, scientists, and researchers fighting COVID-19.

[LEARN MORE](#)

### Apply for Cloud Resources

**SUBMIT**

# RJEŠENJE?



**PUBPEER**  
The online journal club



THE PREPRINT SERVER FOR HEALTH SCIENCES

**medRxiv**



**BMJ**  
Yale



There are 2 articles on this page with PubPeer comments





**THE TROUBLE WITH  
MOST OF US IS THAT  
WE WOULD RATHER  
BE RUINED BY  
PRAISE THAN SAVED  
BY CRITICISM**

**NORMAN VINCENT PEALE**

---





Homolak, J. & Kodvanj, I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. *Int. J. Antimicrob. Agents* 56, 106044 (2020) doi:10.1016/j.ijantimicag.2020.106044.

Clinical Drug Investigation (2021) 41:287–289  
<https://doi.org/10.1007/s40261-021-01007-8>

LETTER TO THE EDITOR



## An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19

Jan Homolak<sup>1</sup> · Ivan Kodvanj<sup>1</sup> · Vladimir Trkulja<sup>1</sup>

Accepted: 23 January 2021 / Published online: 19 February 2021

© The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021

Poslan upit u HZZO  
10.02.2021





Poslan upit u HZZO  
10.02.2021

Odgovor  
HZZO-a  
[24.02.2021.]

Poštovani,

Hrvatski zavod za zdravstveno osiguranje (u daljnjem tekstu: Zavod) zaprimio je zahtjev za pristup informacijama gospodina Ivana Kodvanja, a kojim zahtjevom su zatraženi podaci vezani za istraživanje bolesti uzrokovane virusom SARS-Cov-2.

Zavod ne raspolaže traženim podacima.

Člankom 130. stavkom 1. točkom 17. Zakona o zdravstvenoj zaštiti („Narodne novine“, broj 100/18. i 125/19.) propisano je kako Hrvatski zavod za javno zdravstvo provodi kontinuirano epidemiološko praćenje, sprječavanje i suzbijanje zaraznih bolesti, uključujući koordiniranje i provođenje sustava javnozdravstvene pripravnosti.

Slijedom navedenog, u skladu sa člankom 21. stavkom 1. Zakona o pravu na pristup informacijama („Narodne novine“, broj 25/13. i 85/15.) ustupamo Vam zahtjev gospodina Ivana Kodvanja na nadležno postupanje.

O istom se obavještava i korisnik prava.

S poštovanjem,

Zamjenik službenika za informiranje



Hrvatski zavod za zdravstveno osiguranje  
Croatian Health Insurance Fund

Direkcija  
Muzumlića 5, pta. 107  
10002 Zagreb  
IBAN: 0295922670  
T: +385 (0) 4806 333  
F: +385 (0) 4806 345  
www.hzzo.hr

KLASA: 008-0121-01/08  
URBROJ: 338-01-02-06-21-02  
Zagreb, 24. veljače 2021. godine

HRTVATSKI ZAVOD ZA JAVNO  
ZDRAVSTVO  
10000 Zagreb  
Rokoskičeva 7  
njp službenika za informiranje

PREDMET: Ivan Kodvanj – podaci vezani za bolest uzrokovane virusom SARS-CoV-2;  
– ustupanje zahtjeva

Poštovani,

Hrvatski zavod za zdravstveno osiguranje (u daljnjem tekstu: Zavod) zaprimio je zahtjev za pristup informacijama gospodina Ivana Kodvanja, a kojim zahtjevom su zatraženi podaci vezani za istraživanje bolesti uzrokovane virusom SARS-CoV-2.

Zavod ne raspolaže traženim podacima.

Člankom 130. stavkom 1. točkom 17. Zakona o zdravstvenoj zaštiti („Narodne novine“, broj 100/18. i 125/19.) propisano je kako Hrvatski zavod za javno zdravstvo provodi kontinuirano epidemiološko praćenje, sprječavanje i suzbijanje zaraznih bolesti, uključujući koordiniranje i provođenje sustava javnozdravstvene pripravnosti.

Slijedom navedenog, u skladu sa člankom 21. stavkom 1. Zakona o pravu na pristup informacijama („Narodne novine“, broj 25/13. i 85/15.) ustupamo Vam zahtjev gospodina Ivana Kodvanja na nadležno postupanje.

O istom se obavještava i korisnik prava.

S poštovanjem,

Zamjenik službenika za informiranje

Andrija Hejrgardić, dipl. inf.



Privat: Zahtjev za pristup informacijama


O tome obavijest:  
Ivan Kodvanj, ikodvanj@gmail.com

Upuća preporučeno s povratnicom


Hrvatski zavod za zdravstveno osiguranje  
Muzumlića 5, 10000 Zagreb  
IBAN: 0295922670

Ustanova je upisana u sudski registar  
Trgovačkoga suda u Zagrebu, MB: 080427347  
Revident: Lucian Vlašić, dr.med. spec.











Poštovani,

u vezi Vašeg zahtjeva za pristup informacijama od 01.04.2021. godine, obavještavamo Vas sljedeće.


kako bi se osigurala potpunost i točnost tražene informacije obavještavamo Vas kako u skladu s člankom 22. stavkom 1. točkom 3. Zakona o pravu na pristup informacijama („Narodne novine“, broj 25/13. i 85/15.) produžujemo rok za ostvarivanje prava na pristup informaciji za 15 dana od dana kada je trebalo odlučiti o Vašem zahtjevu.

S poštovanjem,









Poštovani,

osobno se ispričavam na nejavljanju i proteku vremena. Kao zamjenik službenika za informiranje čekao sam odgovor nadležnih Službi Hrvatskog zavoda za zdravstveno osiguranje (u daljnjem tekstu: Zavod) u vezi Vašeg zahtjeva za pristup informacijama.

Tražene podatke Zavod nema u posjedu.

Sukladno odredbama Zakona o pravu na pristup informacijama, o navedenome biti će Vam dostavljeno Rješenje, a na koje će te moći izjaviti žalbu, sukladno uputi o pravnom lijeku.

S poštovanjem,





Sveučilište u Zagrebu  
Medicinski fakultet  
Središnja medicinska knjižnica

2021 **MICCC**  
Medical Information Conference Croatia



Wolters Kluwer

Ovid

# PITANJA ... I JOŠ VAŽNIJE – RJEŠENJA?



@JanHomolak  
homolakjan@gmail.com

